1. Hanna N, Einhorn LH. Testicular cancer: a reflection on 50 years of discovery. J Clin Oncol. 2014;32(28):3085-92. Epub 2014/07/16. doi: 10.1200/JCO.2014.56.0896. PubMed PMID: 25024068.
2. Kurobe M, Kawai K, Suetomi T, Iwamoto T, Waku N, Kawahara T, et al. High prevalence of hypogonadism determined by serum free testosterone level in Japanese testicular cancer survivors. Int J Urol. 2018;25(5):457-62. Epub 2018/02/27. doi: 10.1111/iju.13537. PubMed PMID: 29478250.
3. Znaor A, Lortet-Tieulent J, Jemal A, Bray F. International variations and trends in testicular cancer incidence and mortality. Eur Urol. 2014;65(6):1095-106. Epub 2013/11/26. doi: 10.1016/j.eururo.2013.11.004. PubMed PMID:24268506.
4. Japan Rare Cancer Patient Network. Definition of rare cancers 2020 [2021/9/3]. Available from: https://rarecancersjapan.org/en/rarecancers/.
5. Hayes-Lattin B, Bleyer A. Testicular Cancer. Cancer in Adolescents and Young Adults. Pediatric Oncology2017. p. 307-18.
6. Weijl NI, Rutten MF, Zwinderman AH, Keizer HJ, Nooy MA, Rosendaal FR, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 2000;18(10):2169-78. Epub 2000/05/16. doi: 10.1200/JCO.2000.18.10.2169. PubMed PMID: 10811682.
7. McKiernan JM, Goluboff ET, Liberson GL, Golden R, Fisch H. Rising risk of testicular cancer by birth cohort in the United States from 1973 to 1995. J Urol. 1999;162(2):361-3. Epub 1999/07/20. PubMed PMID: 10411039.
8. McGlynn KA, Devesa SS, Graubard BI, Castle PE. Increasing incidence of testicular germ cell tumors among black men in the United States. J Clin Oncol. 2005;23(24):5757-61. Epub 2005/08/20. doi: 10.1200/JCO.2005.08.227. PubMed PMID: 16110032.
9. Purdue MP, Devesa SS, Sigurdson AJ, McGlynn KA. International patterns and trends in testis cancer incidence. Int J Cancer. 2005;115(5):822-7. Epub 2005/02/11. doi: 10.1002/ijc.20931. PubMed PMID: 15704170.
10. Chien FL, Schwartz SM, Johnson RH. Increase in testicular germ cell tumor incidence among Hispanic adolescents and young adults in the United States. Cancer. 2014;120(17):2728-34. Epub 2014/07/22. doi: 10.1002/cncr.28684. PubMed PMID: 25044313; PubMed Central PMCID: PMCPMC4454545.
11. Stephenson AJ, Gilligan TD. Neoplasms of the Testis. In: Win AJ, Kavoussi LR, Partin AW, Peters CA, editors. Campbell-Walsh Urology, ELEVENTH EDITION. 1. Philadelphia: Elsevier; 2016. p. 784-815.
12. Wood HM, Elder JS. Cryptorchidism and testicular cancer: separating fact from fiction. J Urol. 2009;181(2):452-61. Epub 2008/12/17. doi: 10.1016/j.juro.2008.10.074. PubMed PMID: 19084853.
13. Akre O, Pettersson A, Richiardi L. Risk of contralateral testicular cancer among men with unilaterally undescended testis: a meta analysis. Int J Cancer. 2009;124(3):687-9. Epub 2008/11/01. doi: 10.1002/ijc.23936. PubMed PMID: 18973229.
14. Fossa SD, Chen J, Schonfeld SJ, McGlynn KA, McMaster ML, Gail MH, et al. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst. 2005;97(14):1056-66. Epub 2005/07/21. doi: 10.1093/jnci/dji185. PubMed PMID: 16030303.
15. Harland SJ. Conundrum of the hereditary component of testicular cancer. Lancet. 2000;356(9240):1455-6. Epub 2000/11/18. doi: 10.1016/S0140- 6736(00)02863-4. PubMed PMID: 11081522.
16. Hemminki K, Chen B. Familial risks in testicular cancer as aetiological clues. Int J Androl. 2006;29(1):205-10. Epub 2006/02/10. doi: 10.1111/j.1365- 2605.2005.00599.x. PubMed PMID: 16466541.
17. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs- Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2016;70(1):93-105. Epub 2016/03/05. doi: 10.1016/j.eururo.2016.02.029. PubMed PMID: 26935559.
18. The Japanese Urological Association, The Japanese Society of Pathology, Japan Radiological Society, Japanese Society of Medical Oncology. General Rule for Clinical and Pathological Studies on Testicular Tumors. 4th edn. Tokyo: Kanehara-Shuppan Inc.; 2018.
19. Petersen PM, Giwercman A, Hansen SW, Berthelsen JG, Daugaard G, Rorth M, et al. Impaired testicular function in patients with carcinoma-in-situ of the testis. J Clin Oncol. 1999;17(1):173-9. Epub 1999/08/24. doi: 10.1200/JCO.1999.17.1.173. PubMed PMID: 10458231.
20. Richiardi L, Akre O, Montgomery SM, Lambe M, Kvist U, Ekbom A. Fecundity and twinning rates as measures of fertility before diagnosis of germ-cell testicular cancer. J Natl Cancer Inst. 2004;96(2):145-7. Epub 2004/01/22. doi: 10.1093/jnci/djh012. PubMed PMID: 14734704.
21. von der Maase H, Rorth M, Walbom-Jorgensen S, Sorensen BL, Christophersen IS, Hald T, et al. Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. Br Med J (Clin Res Ed). 1986;293(6559):1398-401. Epub 1986/11/29. doi: 10.1136/bmj.293.6559.1398. PubMed PMID: 3026550; PubMed Central PMCID: PMCPMC1342169.
22. Ulbright TM. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol. 2005;18 Suppl 2:S61-79. Epub 2005/03/12. doi: 10.1038/modpathol.3800310. PubMed PMID: 15761467.
23. Cheville JC. Classification and pathology of testicular germ cell and sex cord-stromal tumors. Urol Clin North Am. 1999;26(3):595-609. Epub 1999/09/24. doi: 10.1016/s0094-0143(05)70201-9. PubMed PMID: 10494291.
24. Balzer BL, Ulbright TM. Spontaneous regression of testicular germ cell tumors: an analysis of 42 cases. Am J Surg Pathol. 2006;30(7):858-65. Epub 2006/07/05. doi: 10.1097/01.pas.0000209831.24230.56. PubMed PMID: 16819328.
25. Looijenga LH, Zafarana G, Grygalewicz B, Summersgill B, Debiec-Rychter M, Veltman J, et al. Role of gain of 12p in germ cell tumour development. APMIS. 2003;111(1):161-71; discussion 72-3. Epub 2003/05/20. doi: 10.1034/j.1600-0463.2003.11101201.x. PubMed PMID: 12752258.
26. Wetherell D, Lawrentschuk N, Gyomber D. Spermatocytic seminoma with sarcoma: an indication for adjuvant chemotherapy in localized disease. Korean J Urol. 2013;54(12):884-7. Epub 2013/12/24. doi: 10.4111/kju.2013.54.12.884. PubMed PMID: 24363873; PubMed Central PMCID: PMCPMC3866295.
27. Al-Obaidy KI, Idrees MT. Testicular Tumors: A Contemporary Update on Morphologic, Immunohistochemical and Molecular Features. Adv Anat Pathol. 2021;28(4):258-75. Epub 2021/04/20. doi: 10.1097/PAP.0000000000000302. PubMed PMID: 33871428.
28. Cheville JC, Sebo TJ, Lager DJ, Bostwick DG, Farrow GM. Leydig cell tumor of the testis: a clinicopathologic, DNA content, and MIB-1 comparison of nonmetastasizing and metastasizing tumors. Am J Surg Pathol. 1998;22(11):1361-7. Epub 1998/11/10. doi: 10.1097/00000478-199811000-00006. PubMed PMID: 9808128.
29. Hao C, Kang C, Kang X, Yu Z, Li T, Xue J. Primary Borderline Mucinous Testicular Tumor: A Case Report and Literature Review. Front Oncol. 2020;10:619774. Epub 2021/03/27. doi: 10.3389/fonc.2020.619774. PubMed PMID: 33767975; PubMed Central PMCID: PMCPMC7986722.
30. Weiss VL, Brock JW, Cajaiba MM. Juvenile xanthogranuloma: an unusual cause of intratesticular mass in childhood. Urology. 2014;83(5):1173-5. Epub 2014/03/04. doi: 10.1016/j.urology.2013.12.034. PubMed PMID: 24582118.
31. Shahab N, Doll DC. Testicular lymphoma. Semin Oncol. 1999;26(3):259-69. Epub 1999/06/22. PubMed PMID: 10375083.
32. Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003;21(1):20-7. Epub 2002/12/31. doi: 10.1200/JCO.2003.11.141. PubMed PMID: 12506165.
33. Al-Obaidy KI, Idrees MT, Grignon DJ, Ulbright TM. Adenocarcinoma of the Rete Testis: Clinicopathologic and Immunohistochemical Characterization of 6 Cases and Review of the Literature. Am J Surg Pathol. 2019;43(5):670-81. Epub 2019/01/25. doi: 10.1097/PAS.0000000000001219. PubMed PMID: 30676333.
34. Sobin LH. TNM: principles, history, and relation to other prognostic factors. Cancer. 2001;91(8 Suppl):1589-92. Epub 2001/04/20. doi: 10.1002/1097-0142(20010415)91:8+<1589::aid-cncr1170>3.0.co;2-k. PubMed PMID: 11309755.
35. van Dijk MR, Steyerberg EW, Habbema JD. Survival of non- seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis. Eur J Cancer. 2006;42(7):820-6. Epub 2006/04/01. doi: 10.1016/j.ejca.2005.08.043. PubMed PMID: 16574403.
36. Davis BE, Herr HW, Fair WR, Bosl GJ. The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. J Urol. 1994;152(1):111-3; discussion 4. Epub 1994/07/01. doi: 10.1016/s0022-5347(17)32830-6. PubMed PMID: 7515445.
37. Oldenburg J, Fossa SD, Nuver J, Heidenreich A, Schmoll HJ, Bokemeyer C, et al. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi125-32. Epub 2013/10/23. doi: 10.1093/annonc/mdt304. PubMed PMID: 24078656.
38. Toner GC, Panicek DM, Heelan RT, Geller NL, Lin SY, Bajorin D, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol. 1990;8(10):1683-94. Epub 1990/10/01. doi: 10.1200/JCO.1990.8.10.1683. PubMed PMID: 2170590.
39. Nitta S, Kawai K, Kimura T, Kandori S, Kawahara T, Kojima T, et al. Advanced germ cell tumor patients undergoing post-chemotherapy retroperitoneal lymph node dissection: Impact of residual teratoma on prognosis. Int J Urol. 2021;28(8):840-7. Epub 2021/06/05. doi: 10.1111/iju.14587. PubMed PMID: 34085325.
40. International Germ Cell Consensus Classification: a prognostic factor- based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997;15(2):594-603. Epub 1997/02/01. doi: 10.1200/JCO.1997.15.2.594. PubMed PMID: 9053482.
41. Gillessen S, Collette L, Daugaard G, de Wit R, Tryakin A, Albany C, et al. Redefining the IGCCCG classification in advanced non-seminoma. Annals of Oncology. 2019;30:v357-v8. doi: 10.1093/annonc/mdz249.002.
42. Kawai K, Miyazaki J. Recent advance in treatment of poor-risk testicular tumor. Japanese Journal of Clinical Urology. 2020;74(10):719-25. doi: 10.11477/mf.1413207010.
43. Kawai K, Ando S, Hinotsu S, Oikawa T, Sekido N, Miyanaga N, et al. Completion and toxicity of induction chemotherapy for metastatic testicular cancer: an updated evaluation of Japanese patients. Jpn J Clin Oncol. 2006;36(7):425-31. Epub 2006/06/23. doi: 10.1093/jjco/hyl053. PubMed PMID: 16790450.
44. Kawai K, Akaza H. Current status of chemotherapy in risk-adapted management for metastatic testicular germ cell cancer. Cancer Sci. 2010;101(1):22-8. Epub 2009/11/20. doi: 10.1111/j.1349-7006.2009.01373.x. PubMed PMID: 19922501.
45. Einhorn LH, Foster RS. Bleomycin, etoposide, and cisplatin for three cycles compared with etoposide and cisplatin for four cycles in good-risk germ cell tumors: is there a preferred regimen? J Clin Oncol. 2006;24(16):2597-8; author reply 8-9. Epub 2006/06/01. doi: 10.1200/JCO.2006.05.6184. PubMed PMID: 16735718.
46. Shiga M, Kawai K, Kojyo K, Kurobe M, Ichioka D, Yoshino T, et al. A Case of Advanced Seminoma in a 79-Year-Old Man Successfully Treated with Etoposide and Cisplatin. Acta Urol Jpn. 2015;61(12):515-8. Epub 2016/01/23. PubMed PMID: 26790767.
47. Inai H, Kawai K, Kojima T, Joraku A, Shimazui T, Yamauchi A, et al. Oncological outcomes of metastatic testicular cancers under centralized management through regional medical network. Jpn J Clin Oncol. 2013;43(12):1249-54. Epub 2013/10/09. doi: 10.1093/jjco/hyt152. PubMed PMID: 24101656.
48. Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol. 2013;24(4):878-88. Epub 2012/11/16. doi: 10.1093/annonc/mds579. PubMed PMID: 23152360; PubMed Central PMCID: PMCPMC3603440.
49. Sekine I. The value of case reports in medical education. Chiba medical journal. 2017;93(1):31-3.
50. Cabinet Office. Annual Report on the Aging Society 2017 (Summary) Tokyo: Cabinet Office, Government of Japan; 2017. Available from: https://www8.cao.go.jp/kourei/english/annualreport/2017/2017pdf_e.html.
51. Nagumo Y, Kandori S, Nishiyama H. Rare Cancers in the Genitourinary Tract. Japanese Journal of Cancer and Chemotherapy. 2020;47(7):1026-30. Epub 2020/07/17. PubMed PMID: 32668844.
52. Tomizuka T, Namikawa K, Higashi T. Characteristics of melanoma in Japan: a nationwide registry analysis 2011-2013. Melanoma Res. 2017;27(5):492-7. Epub 2017/06/14. doi: 10.1097/CMR.0000000000000375. PubMed PMID: 28609317.
53. Kanayama H. Urologic cancer registration. Official Journal of the Japan Association of Endocrine Surgeons and the Japanese Society of Thyroid Surgery. 2014;31(1):44-7. doi: 10.11226/jaesjsts.31.1_44.
54. Higashi T, Nakamura F, Shibata A, Emori Y, Nishimoto H. The national database of hospital-based cancer registries: a nationwide infrastructure to support evidence-based cancer care and cancer control policy in Japan. Jpn J Clin Oncol. 2014;44(1):2-8. Epub 2013/03/02. doi: 10.1093/jjco/hyt013. PubMed PMID: 23448800.
55. Inoue I, Nakamura F, Matsumoto K, Takimoto T, Higashi T. Cancer in adolescents and young adults: National incidence and characteristics in Japan. Cancer Epidemiol. 2017;51:74-80. Epub 2017/10/28. doi: 10.1016/j.canep.2017.10.010. PubMed PMID: 29078121.
56. Okuyama A, Higashi T. Patterns of cancer treatment in different age groups in Japan: an analysis of hospital-based cancer registry data, 2012-2015. Jpn J Clin Oncol. 2018;48(5):417-25. Epub 2018/03/29. doi: 10.1093/jjco/hyy032. PubMed PMID: 29590399.
57. Rosenberg SA. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. Cancer Treat Rep. 1977;61(6):1023-7. Epub 1977/09/01. PubMed PMID: 902260.
58. Campbell CM, Middleton AW, Jr. Malignant gonadal stromal tumor: case report and review of the literature. J Urol. 1981;125(2):257-9. Epub 1981/02/01. doi: 10.1016/s0022-5347(17)54996-4. PubMed PMID: 7009890.
59. Minei S, Fujimura K, Kishimoto Y, Saito T, Okada K, Yukie T. Sex cord/stromal tumor of the testis, incompletely differentiated forms: A case report. Japanese Journal of Clinical Urology. 2002;56(10):827-30. doi: 10.11477/mf.1413903618.
60. Woldu SL, Aydin AM, Rao AV, Hutchinson RC, Singla N, Clinton TN, et al. Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses. Urology. 2018;112:103-11. Epub 2017/10/29. doi: 10.1016/j.urology.2017.08.059. PubMed PMID: 29079210.
61. Bonet AS, Munoz-Delgado EG, Vico FJ, Ruiz JC, Chapado MS. Analysis of clinical-pathologic variables, staging and prognostic groups, and therapeutic results of 106 germ-cell testicular tumors. Arch Esp Urol. 2011;64(10):972-80. Epub 2012/01/10. PubMed PMID: 22228895.
62. Lorenzo L, Marzullo L, Luján S, Rogel R, Broseta E, Boronat F. Principales características clínicas y de supervivencia en una serie de tumores testiculares primarios. Revista Internacional de Andrología. 2017;15(2):39-44. doi: 10.1016/j.androl.2016.07.001.
63. Dusaud M, Durand X, Desfemmes FR, Molimard B, Bayoud Y, Audouin M, et al. A 20-Year Epidemiological Review of Testis Cancer at a French Military Hospital. Mil Med. 2015;180(11):1184-8. Epub 2015/11/06. doi: 10.7205/MILMED-D-14-00604. PubMed PMID: 26540711.
64. Gurney JK, Sarfati D, Stanley J. Obscure etiology, unusual disparity: the epidemiology of testicular cancer in New Zealand. Cancer Causes Control. 2015;26(4):561-9. Epub 2015/02/18. doi: 10.1007/s10552-015-0533-4. PubMed PMID: 25687480.
65. Miki T, Kamoi K, Fujimoto H, Kanayama H, Ohyama C, Suzuki K, et al. Clinical characteristics and oncological outcomes of testicular cancer patients registered in 2005 and 2008: the first large-scale study from the Cancer Registration Committee of the Japanese Urological Association. Int J Urol. 2014;21(8):S1-6. Epub 2014/04/15. doi: 10.1111/iju.12441. PubMed PMID: 24725194.
66. The National Statistics Center. Population and Households of Japan. Final Report of the 2015 Population Census. 2015 [2019/7/17]. Available from: https://www.e-stat.go.jp/en/stat-search/files/.
67. Moller H. Clues to the aetiology of testicular germ cell tumours from descriptive epidemiology. Eur Urol. 1993;23(1):8-13; discussion 4-5. Epub 1993/01/01. doi: 10.1159/000474564. PubMed PMID: 8386660.
68. Stone JM, Cruickshank DG, Sandeman TF, Matthews JP. Trebling of the incidence of testicular cancer in victoria, Australia (1950-1985). Cancer. 1991;68(1):211-9. Epub 1991/07/01. doi: 10.1002/1097-0142(19910701)68:1<211::aid-cncr2820680139>3.0.co;2-q. PubMed PMID: 1646683.
69. Richiardi L, Bellocco R, Adami HO, Torrang A, Barlow L, Hakulinen T, et al. Testicular cancer incidence in eight northern European countries: secular and recent trends. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2157-66. Epub 2004/12/16. PubMed PMID: 15598775.
70. Ruf CG, Isbarn H, Wagner W, Fisch M, Matthies C, Dieckmann KP. Changes in epidemiologic features of testicular germ cell cancer: age at diagnosis and relative frequency of seminoma are constantly and significantly increasing. Urol Oncol. 2014;32(1):33 e1-6. Epub 2013/02/12. doi: 10.1016/j.urolonc.2012.12.002. PubMed PMID: 23395239.
71. Stang A, Rusner C, Stabenow R. Changing epidemiologic features of testicular germ cell cancer in Germany: corroboration at population level. Urol Oncol. 2013;31(8):1839-40. Epub 2013/09/17. doi: 10.1016/j.urolonc.2013.07.007. PubMed PMID: 24035419.
72. Rusner C, Trabert B, Katalinic A, Kieschke J, Emrich K, Stang A, et al. Incidence patterns and trends of malignant gonadal and extragonadal germ cell tumors in Germany, 1998-2008. Cancer Epidemiol. 2013;37(4):370-3. Epub 2013/05/21. doi: 10.1016/j.canep.2013.04.003. PubMed PMID: 23683844; PubMed Central PMCID: PMCPMC4029332.
73. Kawai T, Tanaka Y, Cancer Registration Committee of the Japanese Urological A. Clinical characteristics of testicular germ cell tumors in patients aged 50 years and older: A large-scale study from the Cancer Registration Committee of the Japanese Urological Association. Int J Urol. 2017;24(2):124-8. Epub 2016/12/05. doi: 10.1111/iju.13268. PubMed PMID: 27915468.
74. Dieckmann KP, Skakkebaek NE. Carcinoma in situ of the testis: review of biological and clinical features. Int J Cancer. 1999;83(6):815-22. Epub 1999/12/22. doi: 10.1002/(sici)1097-0215(19991210)83:6<815::aid- ijc21>3.0.co;2-z. PubMed PMID: 10597201.
75. Meeks JJ, Sheinfeld J, Eggener SE. Environmental toxicology of testicular cancer. Urol Oncol. 2012;30(2):212-5. Epub 2012/03/06. doi: 10.1016/j.urolonc.2011.09.009. PubMed PMID: 22385991.
76. Moller MB, d'Amore F, Christensen BE. Testicular lymphoma: a population-based study of incidence, clinicopathological correlations and prognosis. The Danish Lymphoma Study Group, LYFO. Eur J Cancer. 1994;30A(12):1760-4. Epub 1994/01/01. doi: 10.1016/0959-8049(94)00311-r. PubMed PMID: 7880601.
77. Cheah CY, Wirth A, Seymour JF. Primary testicular lymphoma. Blood. 2014;123(4):486-93. Epub 2013/11/28. doi: 10.1182/blood-2013-10-530659. PubMed PMID: 24282217.
78. Dieckmann KP, Richter-Simonsen H, Kulejewski M, Ikogho R, Zecha H, Anheuser P, et al. Testicular Germ-Cell Tumours: A Descriptive Analysis of Clinical Characteristics at First Presentation. Urol Int. 2018;100(4):409-19. Epub 2018/04/13. doi: 10.1159/000488284. PubMed PMID: 29649815; PubMed Central PMCID: PMCPMC6039091.
79. Feldman DR, Voss MH, Jacobsen EP, Jia X, Suarez JA, Turkula S, et al. Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. Cancer. 2013;119(14):2574-
81. Epub 2013/04/23. doi: 10.1002/cncr.28025. PubMed PMID: 23606402.
80. Miller RE, Markt SC, O'Donnell E, Bernard B, Albiges LK, Beard C, et al. Age >/=40 Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended Chemotherapy. Eur Urol Focus. 2017;3(6):621-8. Epub 2017/07/30. doi: 10.1016/j.euf.2016.10.005. PubMed PMID: 28753801.
81. Simpson AB, Paul J, Graham J, Kaye SB. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer. 1998;78(8):1061-6. Epub 1998/10/29. doi: 10.1038/bjc.1998.628. PubMed PMID: 9792151; PubMed Central PMCID: PMCPMC2063168.
82. Woldu SL, Matulay JT, Clinton TN, Singla N, Krabbe L-M, Hutchinson RC, et al. Impact of hospital case volume on testicular cancer outcomes and practice patterns. Urologic Oncology: Seminars and Original Investigations. 2018;36(1):14.e7-.e5. doi: 10.1016/j.urolonc.2017.08.024.
83. Collette L, Sylvester RJ, Stenning SP, Fossa SD, Mead GM, de Wit R, et al. Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst. 1999;91(10):839-46. Epub 1999/05/26. doi: 10.1093/jnci/91.10.839. PubMed PMID: 10340903.
論文の公開元へ
